Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines

Biochemical Pharmacology

Volumn 61, Issue 11, 2001, Pages 1401-1408

  Bergman, Andries M ^a   Munch Petersen, Birgitte ^b   Jensen, Peter Buhl ^c   Sehested, Maxwell ^d   Veerman, Gijsbert ^a   Voorn, Daphne A ^a   Smid, Kees ^a   Pinedo, Herbert M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROSKILDE UNIVERSITY   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d Laboratory Center   (Denmark)

Author keywords

Cytosine arabinoside; Deoxycytidine deaminase; Deoxycytidine kinase; Gemcitabine; Multidrug resistance; Ribonucleoside triphosphate; Thymidine kinase 2

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTARABINE; CYTIDINE TRIPHOSPHATE; DAUNORUBICIN; DEOXYCITIDINE DEAMINASE; DEOXYCITIDINE KINASE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME; GEMCITABINE; GLYCOPROTEIN P; GUANOSINE TRIPHOSPHATE; ISOPROTEIN; MITOCHONDRIAL ENZYME; MULTIDRUG RESISTANCE PROTEIN; RIBONUCLEOSIDE; RIBONUCLEOTIDE; TENIPOSIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ARTICLE; CANCER CELL CULTURE; CATALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CARCINOMA, SMALL CELL; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GUANOSINE TRIPHOSPHATE; HUMANS; LUNG NEOPLASMS; NUCLEOSIDE DEAMINASES; TENIPOSIDE; THYMIDINE KINASE; TUMOR CELLS, CULTURED; URIDINE TRIPHOSPHATE;

EID: 0035370527     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00627-X     Document Type: Article

References (46)

1. Kristjansen P.E., Quistorff B., Spang-Thomsen M., Hansen H.H. Intratumoral pharmacokinetics analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. Ann Oncol. 4:1993;157-160.
2. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Goss G., Stewart D., Tarasoff P., Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. Ann Oncol. 5:1994;283-285.
3. Rassmann I., Thodtmann R., Depenbrock H., Blatter J., Gatzemeier U., Rastetter J., Hanauske A.R. Gemcitabine and etoposide in small cell lung cancer phase I and phase II trials . Semin Oncol. 24:(2 Suppl. 7):1997;S7-78.
4. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
5. Bergman A.M., Pinedo H.M., Jongsma A.P., Brouwer M., Ruiz van Haperen V.W., Veerman G., Leyva A., Eriksson S., Peters G.J. Decreased resistance to gemcitabine of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines role of altered activity and substrate specificity of deoxycytidine kinase . Biochem Pharmacol. 57:1999;397-406.
6. Eriksson S., Kierdaszuk B., Munch-Petersen B., Oberg B., Johansson N.G. Comparison of the substrate specifities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun. 176:1991;586-592.
7. Datta N.S., Shewach D.S., Hurley M.C., Mitchell B.S., Fox I.H. Human T-lymphoblast deoxycytidine kinase purification and properties . Biochemistry. 28:1989;114-123.
8. Nielsen S.E., Munch-Petersen B., Mejer J. Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes. Leuk Res. 19:1995;443-447.
9. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol. 46:1993;762-766.
10. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
11. Ross D.D., Chen S.R., Cuddy D.P. Effects of 1-β-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res. 50:1990;2658-2666.
12. Baker C.H., Banzon J., Bollinger J.M., Stubbe J. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorodeoxycytidine 5′-diphosphates potent mechanism-based inhibitors of ribonucleotide reductase . J Med Chem. 34:1991;1879-1884.
13. Plunkett W., Huang O., Xu Y.Z., Heinemann V., Grunewald R., Ghandi V. Gemcitabine metabolism, mechanisms of action, and self-potentiation . Semin Oncol. 22:(Suppl. 11):1995;42-46.
14. Heinemann V., Schulz L., Issels R.D., Plunkett W. Gemcitabine a modulator of intracellular nucleotide and deoxynucleotide metabolism . Semin Oncol. 22:(4 Suppl. 11):1995;11-18.
15. Pinedo H.M., Giaccone G. P-glycoprotein a marker of cancer cell behavior . N Eng J Med. 333:1995;1417-1419.
16. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
17. Danks M.K., Yalowich J.C., Beck W.T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
18. Mackey J.R., Mani R.S., Selner M., Mowle D., Young J.D., Belt J.A., Crawford C.R., Cass C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestations of toxicity in cancer cell lines. Cancer Res. 58:1998;4349-4357.
19. Young L.C., Campling B.G., Voskoglou-Nomikos T., Cole S.P., Deeley R.G., Gerlach J.H. Expression of multidrug resistance protein-related genes in lung cancer correlation with drug response . Clin Cancer Res. 5:1999;673-680.
20. Wright S.R., Boag A.H., Valdimarsson G., Hipfner D.R., Campling B.G., Cole S.P., Deeley R.G. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res. 4:1998;2279-2289.
21. Izquierdo M.A., Shoemaker R.H., Flens M.J., Scheffer G.L., Wu L., Prather T.R., Scheper R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer. 65:1996;230-237.
22. Savaraj N., Wu C.J., Xu R., Lampidis T., Lai S., Donnelly E., Solomon J., Feun L.G. Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol. 20:1997;398-403.
23. Beck W.T., Cirtain M.C., Danks M.K., Felsted R.L., Safa A.R., Wolverton J.S., Suttle D.P., Trent J.M. Pharmacological, molecular, and cytogenetic analysis of atypical multidrug-resistant human leukemic cells. Cancer Res. 47:1987;5455-5460.
24. Jensen P.B., Holm B., Sorensen M., Christensen I.J., Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin . Br J Cancer. 75:1997;869-877.
25. de Leij L., Postmus P.E., Buys C.H., Elema J.D., Ramaekers F., Poppema S., Brouwer M., van der Veen A.Y., Mesander G., The T.H. Characterization of three new variant cell lines derived from small cell carcinoma of the lung. Cancer Res. 45:1985;6024-6033.
26. Carney D.N., Gazdar A.F., Bepler G., Guccion J.G., Marangos P.J., Moody T.W., Zweig M.H., Minna J.D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45:1985;2913-2923.
27. Jensen P.B., Sorensen B.S., Sehested M., Demant E.J., Kjeldsen E., Friche E., Hansen H.H. Different modes of anthracycline interaction with topoisomerase II separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance . Biochem Pharmacol. 45:1993;2025-2035.
28. Jensen P.B., Vindelov L., Roed H., Demant E.J., Sehested M., Skovsgaard T., Hansen H.H. In vitro evaluation of the potential of aclarubin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer. 60:1989;838-844.
29. Ruiz van Haperen V.W., Veerman G., Braakhuis B.J., Vermorken J.B., Boven E., Leyva A., Peters G.J. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer. 29A:1993;2132-2137.
30. Ruiz van Haperen V.W., Veerman G., Boven E., Noordhuis P., Vermorken J.B., Peters G.J. Schedule dependence of sensitivity of 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol. 48:1994;1327-1339.
31. Noordhuis P., Kazemier K.M., Kaspers G.J., Peters G.J. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leuk Res. 20:1996;127-134.
32. Hunting D., Henderson J.F. Determination of deoxyribonucleoside triphosphates using DNA polymerase a critical evaluation . Can J Biochem. 59:1981;723-727.
33. Peters G.J., De Abreu R.A., Oosterhof A., Veerkamp J.H. Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. Biochim Biophys Acta. 759:1983;7-15.
34. Sherman P.A., Fyfe J.A. Enzymatic assay for deoxyribonucleotide triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 180:1989;222-226.
35. Iwasaki H., Huang P., Keating M.J., Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 90:1997;270-278.
36. van Moorsel C.J., Pinedo H.M., Veerman G., Guechev A., Smid K., Loves W.J., Vermorken J.B., Postmus P.E., Peters G.J. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol. 57:1999;407-415.
37. Jensen P.B., Roed H., Sehested M., Demant E.J., Vindeløv L., Christensen I.J., Hansen H.H. Doxorubicin sensitivity pattern in a panel of small cell lung cancer cell lines correlation to etoposide and vincristine and inverse correlation to carmustine sensitivity . Cancer Chem Pharmacol. 31:1992;46-53.
38. Hait W.N., Choudbury S., Srimatkanda S., Murren J.R. Sensitivity of K562 human chronic myelogeneous leukemia cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiation agents. J Clin Invest. 91:1993;2207-2215.
39. Sharom F.S., Yu X., Doige C.A. Functional reconstruction of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem. 268:1993;24197-24202.
40. Grant S., Turner A., Nelms P., Yanovich S. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-β-D-arabinofuranosylcytosine. Leukemia. 9:1995;808-814.
41. Schuurhuis G.J., Broxterman H.J., Ossenkoppele G.J., Baak J.P., Eekman C.A., Kuiper C.M., Feller N., van Heijningen T.H., Klumper E., Pieters R., Lankelma J., Pinedo H.M. Functional multidrug resistance phenotype associated with combined overexpression of PgP/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res. 1:1995;81-93.
42. Sasvári-Székely M., Spasokoukotskaja T., Szóke M., Csapó Z., Turi Á., Szántó I., Eriksson S., Staub M. Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2′-deoxyadenosine (Cladribine) in human lymphocytes. Biochem Pharmacol. 56:1998;1175-1179.
43. Wang L., Munch-Petersen B., Herrstrom Sjoberg A., Hellman U., Bergman T., Jornvall H., Eriksson S. Human thymidine kinase 2 molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates . FEBS Lett. 443:1999;170-174.
44. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Pinedo H.M., Peters G.J. Regulatory effects of CTP and UTP on deoxycytidine kinase activity in solid tumor cell lines. Biochem Pharmacol. 51:1996;911-918.
45. van Moorsel C.J., Bergman A.M., Veerman G., Voorn D.A., Ruiz van Haperen V.W., Kroep J.R., Pinedo H.M., Peters G.J. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta. 1474:2000;5-12.
46. Hughes T.L., Hahn T.M., Reynolds K.K., Shewach D.S. Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry. 36:1997;7540-7547.